Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

NCT07627698 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Melanoma
Metastatic Cutaneous Melanoma
Metastatic Uveal Melanoma

Interventions

BIOLOGICAL: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Beijing Biotech